Measurement of myocardial infarct size from plasma fatty acid-binding protein or myoglobin, using individually estimated clearance rates

被引:32
作者
de Groot, MJM
Wodzig, KWH
Simoons, ML
Glatz, JFC
Hermens, WT
机构
[1] Maastricht Univ, Cardiovasc Res Inst Maastricht, NL-6200 MD Maastricht, Netherlands
[2] Acad Hosp Maastricht, Dept Clin Chem, Maastricht, Netherlands
[3] Erasmus Univ, Thoraxctr, NL-3000 DR Rotterdam, Netherlands
关键词
enzyme (kinetics); infarction; renal function;
D O I
10.1016/S0008-6363(99)00199-6
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: In patients with acute myocardial infarction (AMI), estimation of infarct size from the early markers, fatty acid-binding protein (FABP) and myoglobin (MYO), usually assumes average (fixed) rate constants (FCR) for protein clearance from plasma. However, individual variation in FCR is large. Renal dysfunction causes slower clearance of FABP and MYO from plasma and, hence, overestimation of infarct size in 20-25% of patients. We investigated whether or not more accurate values of infarct size could be obtained with individually estimated clearance rates. Methods: Concentrations of FABP and MYO and, for comparison, activities of the established cardiac markers, creatine kinase (CK) and alpha-hydroxybutyrate dehydrogenase (HBDH), were assayed in serial plasma samples from 138 patients with AMI, Individual FCR values of FABP and MYO were estimated from plasma creatinine concentrations, sex and age. Results: Individual FCR values varied from 0.4 to 2.4 h(-1). Use of these individual FCR values significantly improved the correlation between infarct size, as estimated from FABP or MYO on the one hand, and from CK and HBDH on the other. Approximately equal estimates of infarct size were obtained for all four marker proteins. Conclusions: Using individually estimated clearance rates, renal insufficiency no longer hampers calculation of infarct size from FABP and MYO, and reliable estimates of total myocardial damage can be obtained within 24 h after first symptoms. (C) 1999 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:315 / 324
页数:10
相关论文
共 32 条
[21]  
VANDERLAARSE A, 1989, EUR J CLIN INVEST, V19, P192
[22]   THE (ISO) ENZYME-ACTIVITIES OF LACTATE-DEHYDROGENASE, ALPHA-HYDROXYBUTYRATE DEHYDROGENASE, CREATINE-KINASE AND ASPARTATE-AMINOTRANSFERASE IN HUMAN MYOCARDIAL BIOPSIES AND AUTOPSIES [J].
VANDERLAARSE, A ;
DIJKSHOORN, NJ ;
HOLLAAR, L ;
CASPERS, T .
CLINICA CHIMICA ACTA, 1980, 104 (03) :381-391
[23]  
VANDERVEEN FH, 1988, CARDIOVASC RES, V22, P611
[24]   DISCRIMINATION BETWEEN MYOCARDIAL AND SKELETAL-MUSCLE INJURY BY ASSESSMENT OF THE PLASMA RATIO OF MYOGLOBIN OVER FATTY-ACID-BINDING PROTEIN [J].
VANNIEUWENHOVEN, FA ;
KLEINE, AH ;
WODZIG, WH ;
HERMENS, WT ;
KRAGTEN, HA ;
MAESSEN, JG ;
PUNT, CD ;
VANDIEIJEN, MP ;
VANDERVUSSE, GJ ;
GLATZ, JFC .
CIRCULATION, 1995, 92 (10) :2848-2854
[25]   ENZYMATIC ASSESSMENT OF MYOCARDIAL NECROSIS AFTER CARDIAC-SURGERY - DIFFERENTIATION FROM SKELETAL-MUSCLE DAMAGE, HEMOLYSIS, AND LIVER-INJURY [J].
WILLEMS, GM ;
VANDERVEEN, FH ;
HUYSMANS, HA ;
FLAMENG, W ;
DEMEYERE, R ;
VANDERLAARSE, A ;
VANDERVUSSE, GJ ;
HERMENS, WT .
AMERICAN HEART JOURNAL, 1985, 109 (06) :1243-1252
[26]   QUANTITATIVE-ANALYSIS OF PLASMA ENZYME LEVELS BASED UPON SIMULTANEOUS DETERMINATION OF DIFFERENT ENZYMES [J].
WILLEMS, GM ;
VISSER, MP ;
KRILL, MTA ;
HERMENS, WT .
CARDIOVASCULAR RESEARCH, 1982, 16 (03) :120-131
[27]   Thrombolytic therapy does not change the release ratios of enzymatic and non-enzymatic myocardial marker proteins [J].
Wodzig, KWH ;
Kragten, JA ;
Modrzejewski, W ;
Gorski, J ;
van Dieijen-Visser, MP ;
Glatz, JFC ;
Hermens, WT .
CLINICA CHIMICA ACTA, 1998, 272 (02) :209-223
[28]   One-step enzyme-linked immunosorbent assay (ELISA) for plasma fatty acid-binding protein [J].
Wodzig, KWH ;
Pelsers, MMAL ;
vanderVusse, GJ ;
Roos, W ;
Glatz, JFC .
ANNALS OF CLINICAL BIOCHEMISTRY, 1997, 34 :263-268
[29]  
Wodzig KWH, 1997, EUR J CLIN CHEM CLIN, V35, P191
[30]  
[No title captured]